 Jeffrey Kern
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 13 | 2019 | 320 | 2.640 |
Why?
| | Neuregulin-1 | 8 | 2019 | 43 | 2.410 |
Why?
| | Lung Neoplasms | 22 | 2022 | 2220 | 2.280 |
Why?
| | Lung | 12 | 2019 | 3664 | 1.570 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 15 | 2022 | 968 | 1.360 |
Why?
| | Signal Transduction | 10 | 2019 | 4709 | 1.250 |
Why?
| | Respiratory Mucosa | 4 | 2014 | 254 | 1.190 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2022 | 156 | 1.020 |
Why?
| | Acute Lung Injury | 3 | 2012 | 310 | 0.960 |
Why?
| | ErbB Receptors | 7 | 2014 | 569 | 0.850 |
Why?
| | Epithelium | 2 | 2019 | 305 | 0.740 |
Why?
| | Receptor, ErbB-3 | 5 | 2007 | 42 | 0.710 |
Why?
| | Adult Stem Cells | 1 | 2019 | 35 | 0.700 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2020 | 83 | 0.690 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 102 | 0.660 |
Why?
| | Adenocarcinoma | 5 | 2019 | 812 | 0.660 |
Why?
| | Neuroendocrine Cells | 2 | 2016 | 30 | 0.650 |
Why?
| | Immunotherapy | 2 | 2022 | 493 | 0.620 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 317 | 0.600 |
Why?
| | Tomography, X-Ray Computed | 7 | 2015 | 2436 | 0.580 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 401 | 0.560 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 407 | 0.550 |
Why?
| | Interleukin-6 | 1 | 2019 | 688 | 0.520 |
Why?
| | Adherens Junctions | 1 | 2014 | 26 | 0.510 |
Why?
| | STAT3 Transcription Factor | 4 | 2009 | 189 | 0.470 |
Why?
| | B-Lymphocyte Subsets | 1 | 2014 | 66 | 0.470 |
Why?
| | Pulmonary Fibrosis | 2 | 2007 | 303 | 0.460 |
Why?
| | Immunity, Humoral | 1 | 2014 | 117 | 0.450 |
Why?
| | Cell Adhesion | 1 | 2014 | 443 | 0.450 |
Why?
| | beta Catenin | 1 | 2014 | 219 | 0.440 |
Why?
| | Blood Coagulation Factors | 1 | 2012 | 43 | 0.430 |
Why?
| | Protein C | 1 | 2012 | 44 | 0.420 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2019 | 610 | 0.420 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 20 | 0.420 |
Why?
| | Smad3 Protein | 1 | 2011 | 47 | 0.400 |
Why?
| | Smad2 Protein | 1 | 2011 | 39 | 0.400 |
Why?
| | Neoplasm Staging | 7 | 2022 | 1223 | 0.400 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 367 | 0.370 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 285 | 0.370 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 164 | 0.370 |
Why?
| | Neoplasms | 2 | 2021 | 2179 | 0.360 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 613 | 0.350 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 176 | 0.350 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 360 | 0.350 |
Why?
| | Lung Diseases | 2 | 2016 | 718 | 0.340 |
Why?
| | Permeability | 4 | 2014 | 156 | 0.340 |
Why?
| | Quinazolines | 5 | 2014 | 245 | 0.330 |
Why?
| | Prenylation | 1 | 2008 | 2 | 0.320 |
Why?
| | Antibodies, Monoclonal | 4 | 2007 | 1284 | 0.310 |
Why?
| | Humans | 42 | 2022 | 118974 | 0.310 |
Why?
| | Epithelial Cells | 2 | 2011 | 963 | 0.300 |
Why?
| | Phosphorylation | 5 | 2019 | 1633 | 0.280 |
Why?
| | Piperidines | 1 | 2008 | 171 | 0.280 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 811 | 0.280 |
Why?
| | Tomography, Emission-Computed | 2 | 2003 | 58 | 0.270 |
Why?
| | Epidermal Growth Factor | 3 | 2012 | 173 | 0.260 |
Why?
| | Mass Screening | 1 | 2012 | 1052 | 0.250 |
Why?
| | Pyridines | 1 | 2008 | 440 | 0.240 |
Why?
| | Autocrine Communication | 1 | 2004 | 42 | 0.240 |
Why?
| | Mediastinal Neoplasms | 1 | 2003 | 35 | 0.230 |
Why?
| | Morphogenesis | 1 | 2004 | 167 | 0.230 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 2851 | 0.230 |
Why?
| | Genetic Therapy | 1 | 2005 | 267 | 0.230 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 341 | 0.220 |
Why?
| | ADAM17 Protein | 2 | 2012 | 31 | 0.210 |
Why?
| | Cell Proliferation | 4 | 2015 | 2275 | 0.200 |
Why?
| | Cell Line | 4 | 2014 | 2707 | 0.200 |
Why?
| | Animals | 10 | 2021 | 33381 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2002 | 131 | 0.200 |
Why?
| | ADAM Proteins | 2 | 2012 | 59 | 0.200 |
Why?
| | Trans-Activators | 1 | 2004 | 373 | 0.200 |
Why?
| | Radiopharmaceuticals | 1 | 2002 | 194 | 0.200 |
Why?
| | RNA Interference | 2 | 2014 | 460 | 0.190 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 86 | 0.190 |
Why?
| | Drug Eruptions | 1 | 2020 | 26 | 0.190 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 827 | 0.180 |
Why?
| | Recombinant Proteins | 3 | 2011 | 1308 | 0.180 |
Why?
| | Etoposide | 1 | 2020 | 149 | 0.180 |
Why?
| | Enzyme Induction | 1 | 2019 | 94 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2019 | 77 | 0.180 |
Why?
| | Tight Junctions | 2 | 2014 | 69 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 144 | 0.170 |
Why?
| | Skin Diseases | 1 | 2021 | 125 | 0.170 |
Why?
| | Radiosurgery | 1 | 2022 | 318 | 0.170 |
Why?
| | Antigens | 1 | 2021 | 320 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 36 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 197 | 0.170 |
Why?
| | Sirolimus | 1 | 2020 | 195 | 0.170 |
Why?
| | Cisplatin | 1 | 2020 | 271 | 0.170 |
Why?
| | Cells, Cultured | 3 | 2019 | 4077 | 0.170 |
Why?
| | Transfection | 3 | 2011 | 888 | 0.160 |
Why?
| | Enzyme Activation | 2 | 2014 | 828 | 0.160 |
Why?
| | Mice | 6 | 2019 | 15520 | 0.160 |
Why?
| | Hyperplasia | 2 | 2016 | 170 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 740 | 0.150 |
Why?
| | Cell Lineage | 1 | 2019 | 318 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 369 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2019 | 2657 | 0.150 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 681 | 0.150 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1346 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 112 | 0.150 |
Why?
| | Female | 13 | 2017 | 61565 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2017 | 194 | 0.140 |
Why?
| | Lung Diseases, Obstructive | 1 | 2016 | 44 | 0.140 |
Why?
| | Mutation | 4 | 2014 | 3457 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 336 | 0.140 |
Why?
| | Research Report | 1 | 2016 | 75 | 0.130 |
Why?
| | Drug Synergism | 2 | 2008 | 339 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 982 | 0.130 |
Why?
| | Bleomycin | 2 | 2007 | 228 | 0.130 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 26 | 0.130 |
Why?
| | Electric Impedance | 1 | 2014 | 101 | 0.120 |
Why?
| | ral GTP-Binding Proteins | 1 | 2013 | 5 | 0.120 |
Why?
| | Transcriptome | 1 | 2019 | 756 | 0.120 |
Why?
| | Medical Oncology | 1 | 2016 | 229 | 0.120 |
Why?
| | Bronchiolitis | 1 | 2015 | 83 | 0.120 |
Why?
| | Male | 12 | 2017 | 57801 | 0.120 |
Why?
| | Protein Binding | 1 | 2019 | 1975 | 0.110 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 520 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1774 | 0.110 |
Why?
| | ras Proteins | 1 | 2013 | 141 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 164 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2017 | 770 | 0.110 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 564 | 0.110 |
Why?
| | History, 20th Century | 1 | 2013 | 281 | 0.110 |
Why?
| | Blotting, Western | 3 | 2013 | 1194 | 0.110 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 24 | 0.100 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 143 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 984 | 0.100 |
Why?
| | Cell Shape | 1 | 2011 | 57 | 0.100 |
Why?
| | Blood-Air Barrier | 1 | 2011 | 9 | 0.100 |
Why?
| | Biopsy, Needle | 1 | 2011 | 190 | 0.100 |
Why?
| | Cellular Senescence | 1 | 2012 | 151 | 0.100 |
Why?
| | Survival Rate | 4 | 2013 | 1720 | 0.100 |
Why?
| | Collagen Type I | 1 | 2011 | 114 | 0.090 |
Why?
| | Fibronectins | 1 | 2011 | 114 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 618 | 0.090 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 2009 | 8 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 186 | 0.090 |
Why?
| | Tumor Cells, Cultured | 3 | 2013 | 874 | 0.090 |
Why?
| | Bronchoscopy | 1 | 2011 | 247 | 0.090 |
Why?
| | Middle Aged | 7 | 2017 | 27617 | 0.090 |
Why?
| | Vena Cava, Superior | 1 | 2009 | 21 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2011 | 3730 | 0.090 |
Why?
| | Coronary Vessel Anomalies | 1 | 2009 | 29 | 0.090 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 384 | 0.090 |
Why?
| | Global Health | 1 | 2011 | 310 | 0.090 |
Why?
| | Asthma | 1 | 2022 | 2158 | 0.080 |
Why?
| | Transcriptional Activation | 1 | 2011 | 348 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2016 | 829 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 867 | 0.080 |
Why?
| | Time Factors | 2 | 2011 | 6412 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2011 | 277 | 0.080 |
Why?
| | Antigens, CD | 1 | 2011 | 460 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2011 | 379 | 0.080 |
Why?
| | Molecular Chaperones | 1 | 2009 | 174 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2012 | 545 | 0.080 |
Why?
| | Colorimetry | 1 | 2008 | 14 | 0.080 |
Why?
| | Oncogene Protein v-akt | 1 | 2008 | 25 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 58 | 0.080 |
Why?
| | Mesothelioma | 1 | 2008 | 32 | 0.080 |
Why?
| | Indicators and Reagents | 1 | 2008 | 100 | 0.080 |
Why?
| | Abnormalities, Multiple | 1 | 2009 | 181 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 83 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2017 | 6561 | 0.080 |
Why?
| | Azacitidine | 1 | 2008 | 119 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1244 | 0.070 |
Why?
| | Aged | 6 | 2017 | 19657 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1527 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2007 | 4908 | 0.070 |
Why?
| | Contrast Media | 1 | 2009 | 373 | 0.070 |
Why?
| | Nitrates | 1 | 2006 | 78 | 0.070 |
Why?
| | DNA, Complementary | 1 | 2006 | 268 | 0.070 |
Why?
| | Biomarkers | 2 | 2017 | 3588 | 0.070 |
Why?
| | Prognosis | 5 | 2017 | 3443 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 1137 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1390 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2009 | 1167 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2003 | 307 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2012 | 1178 | 0.070 |
Why?
| | Collagen | 1 | 2007 | 433 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3171 | 0.060 |
Why?
| | Tyrphostins | 1 | 2004 | 16 | 0.060 |
Why?
| | Flavonoids | 1 | 2004 | 71 | 0.060 |
Why?
| | Organ Culture Techniques | 1 | 2004 | 149 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2004 | 81 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2008 | 1085 | 0.060 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 408 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2003 | 69 | 0.060 |
Why?
| | DNA Methylation | 1 | 2008 | 503 | 0.060 |
Why?
| | Drug Combinations | 1 | 2004 | 291 | 0.060 |
Why?
| | Kinetics | 1 | 2006 | 1624 | 0.060 |
Why?
| | Apoptosis | 2 | 2013 | 2484 | 0.060 |
Why?
| | Prospective Studies | 3 | 2022 | 6471 | 0.060 |
Why?
| | Adult | 6 | 2016 | 31512 | 0.050 |
Why?
| | Iowa | 1 | 2002 | 26 | 0.050 |
Why?
| | Histoplasmosis | 1 | 2002 | 15 | 0.050 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 703 | 0.050 |
Why?
| | Base Sequence | 1 | 2006 | 2159 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 142 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 36 | 0.050 |
Why?
| | Cell Polarity | 1 | 2003 | 133 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 776 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2022 | 9342 | 0.050 |
Why?
| | Survival Analysis | 1 | 2005 | 1267 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 544 | 0.050 |
Why?
| | Inflammation | 1 | 2012 | 2566 | 0.050 |
Why?
| | United States | 2 | 2022 | 12555 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 1868 | 0.050 |
Why?
| | Fatigue | 1 | 2022 | 297 | 0.050 |
Why?
| | Steroids | 1 | 2021 | 153 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2006 | 1059 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2005 | 2025 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2002 | 455 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2021 | 225 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2015 | 12978 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1384 | 0.040 |
Why?
| | Biopsy | 2 | 2016 | 1079 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1795 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2017 | 136 | 0.040 |
Why?
| | DNA | 1 | 2004 | 1388 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2014 | 671 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2017 | 278 | 0.040 |
Why?
| | Disease Progression | 2 | 2016 | 2490 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2326 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2017 | 454 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2014 | 71 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 1974 | 0.030 |
Why?
| | Nitriles | 1 | 2014 | 155 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1067 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 195 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 128 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 237 | 0.030 |
Why?
| | Pregnancy | 1 | 2004 | 5691 | 0.030 |
Why?
| | Protein Kinases | 1 | 2014 | 310 | 0.030 |
Why?
| | Mice, Nude | 1 | 2013 | 663 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 409 | 0.030 |
Why?
| | Chronic Disease | 1 | 2016 | 1636 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 588 | 0.020 |
Why?
| | Communication | 1 | 2016 | 761 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 76 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2009 | 161 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 185 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 287 | 0.020 |
Why?
| | Plasmids | 1 | 2009 | 355 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2003 | 1691 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1810 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2007 | 32 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 556 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 522 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 872 | 0.020 |
Why?
| | Mediastinoscopy | 1 | 2005 | 3 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1012 | 0.020 |
Why?
| | Trastuzumab | 1 | 2005 | 92 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 842 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1323 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2003 | 91 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 963 | 0.010 |
Why?
| | Infant | 1 | 2016 | 8293 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1474 | 0.010 |
Why?
| | Trachea | 1 | 2003 | 226 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 567 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2005 | 667 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 3057 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2003 | 2478 | 0.010 |
Why?
| | Calcium | 1 | 2003 | 1169 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 2003 | 772 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5392 | 0.010 |
Why?
|
|
Kern's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|